AzTrials
AzTrials

No ConditionNCT07320742

Fast vs. Slow Pranayama for Breathing, Heart, Balance, and Well-Being in Students

A study testing Slow Pranayama and Fast Pranayama in people with No Condition, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to compare the effects of slow and rapid pranayama techniques on respiratory, cardiovascular, balance, and psychosocial parameters in healthy adults aged 18-35 years. Read more about this study

Who is it for?
Ages 18 to 35 yearsHealthy volunteers can take part
Conditions the study is for
No Condition
What is being tested?
Slow Pranayama and Fast Pranayama
Could I receive a placebo?
No, everyone receives an active treatment
How many people
74 participants
Where
1 siteTurkey (Türkiye)
Study dates
16 Aug 2025to 5 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Between age 18-35

Who cannot join

  • Subjects who have practiced yoga techniques in the last year.
  • Subjects with a history of previous or current organic disease.
  • Subjects who cannot practice pranayama due to physical abnormalities.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Istanbul Medipol University

    Istanbul, Istanbul, 34810

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison of the Effects of Fast and Slow Pranayama Techniques on Respiratory, Cardiovascular, Balance, and Psychosocial Parameters in University Students

The goal of this clinical trial is to compare the effects of slow and rapid pranayama techniques on respiratory, cardiovascular, balance, and psychosocial parameters in healthy adults aged 18-35 years.

The main questions it aims to answer are:

Read more

Do slow and rapid pranayama techniques produce different improvements in lung volumes and peak cough flow?

Does slow pranayama lead to greater improvements in oxygen saturation and cardiovascular parameters, while rapid pranayama provides greater gains in balance and respiratory flow values?

Researchers will compare a slow pranayama group (n = 39) and a rapid pranayama group (n = 39) to determine how breathing speed influences physiological and psychosocial outcomes.

Participants will:

Be randomly assigned to one of two groups (slow or rapid pranayama).

Practice their assigned pranayama techniques for 25-30 minutes, 4 days per week for 12 weeks (one supervised, three home-based sessions).

Undergo pre- and post-intervention assessments including spirometry (FVC, FEV₁, FEF25%-75%, PEF), oxygen saturation, peak cough flow, blood pressure, heart rate, balance tests (single-leg stance, Y-Balance Test), and validated questionnaires for perceived stress, anxiety, depression, fatigue, and sleep quality.

This study aims to clarify how controlled breathing speed influences respiratory efficiency, cardiovascular regulation, postural stability, and mental well-being in young adults, contributing to evidence-based recommendations for integrating pranayama into stress-management and preventive rehabilitation programs.

Conditions
No Condition
Being tested
Slow Pranayama, Fast Pranayama
Keywords
pranayama, pulmonary function test, breathing exercise, oxygen saturation, Stress, Psychological, postural balance
Medical subject headings
Stress, Psychological

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Slow PranayamaBehavioural

    Participants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions typically take place as follows:

    Participants in the Slow Pranayama Group will practice the Anuloma Viloma, Savitri, and Ujjayi breathing techniques. Slow pranayama breathing will be practiced for two minutes, with one-minute rests between each breathing technique, for a total of three cycles. Each cycle will last approximately nine minutes. Participants in both groups will rest in savasana for 10 minutes at the end of the session.

    No drugs or devices are used. The intervention is a controlled breathing exercise technique.

  • Fast PranayamaBehavioural

    Participants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions will typically be conducted as follows:

    Participants in the Fast Pranayama Group will practice Kapalabhati, Bhastrika, and Agnisar breathing. Each breathing technique will be practiced for one minute, followed by a one-minute rest. This will be practiced for a total of four cycles. Each cycle will last approximately six minutes.

    No drugs or devices are used. The intervention is a controlled breathing exercise technique.

Study groups in NCT07320742
Study groupRoleWhat they receive
Slow Pranayama GroupExperimentalNot described
Receives: Behavioral: Slow Pranayama
Fast Pranayama GroupExperimentalNot described
Receives: Behavioral: Fast Pranayama

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Forced Expiratory Flow at 25-75% of FVC (FEF25-75)

    FEF25-75 is the average flow rate during the middle half of the FVC maneuver. It is often considered a sensitive indicator of small airway function. Measurements will be carried out using the COSMED PONY FX (Italy) device, ensuring compliance with ATS/ERS standards. The values will be recorded in liters per second (L/s).

    Measured: From enrollment to the end of treatment at 12 weeks

Secondary outcomes (14)
  1. Forced Vital Capacity (FVC)

    Forced Vital Capacity (FVC) represents the maximum volume of air that can be forcibly expelled from the lungs after taking the deepest possible breath. Measurements will be performed in accordance with ATS/ERS guidelines. All pulmonary function measurements will be performed using a spirometer (COSMED PONY FX®, Italy). The highest value obtained from three acceptable and repeatable maneuvers will be recorded in liters (L).

    Measured: From enrollment to the end of treatment at 12 weeks

  2. Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 measures the volume of air exhaled during the first second of the FVC maneuver. It is a critical indicator of airway patency and respiratory muscle function. Data collection will be conducted using the COSMED PONY FX (Italy) device, following the ATS/ERS standardization guidelines. Results will be expressed in liters (L).

    Measured: From enrollment to the end of treatment at 12 weeks

  3. FEV1/FVC Ratio

    This parameter represents the ratio of FEV1 to FVC, which is used to differentiate between obstructive and restrictive ventilatory patterns. The measurements will be obtained using the COSMED PONY FX (Italy) spirometer, adhering to ATS/ERS guidelines. The result is expressed as a decimal ratio or percentage.

    Measured: From enrollment to the end of treatment at 12 weeks

  4. Peak Expiratory Flow (PEF)

    Peak Expiratory Flow (PEF) is the maximum flow rate achieved during a forced expiratory maneuver starting from full inspiration. It reflects the caliber of the large airways and the strength of the expiratory muscles. The measurements will be recorded using the COSMED PONY FX (Italy) spirometer according to ATS/ERS criteria, with the highest value reported in liters per second (L/s) or liters per minute (L/min).

    Measured: From enrollment to the end of treatment at 12 weeks

  5. Peak Cough Flow (PCF)

    Peak cough flow (PCF) will be assessed using a handheld flow meter (Expirite® DL-F03). For all primary measurements, the highest value obtained from three replicates will be used in the analysis.

    Measured: From enrollment to the end of treatment at 12 weeks.

  6. Oxygen Saturation

    It will be evaluated with a pulse oximeter (Freely SHO-3002) attached to the fingertip.

    Measured: From enrollment to the end of treatment at 12 weeks

  7. Blood Pressure

    Cardiovascular parameters will be measured after participants rest in a supine position for 10 minutes. Systolic and diastolic blood pressure measurements will be taken with a non-invasive OMRON M2 Intelli IT HEM-7143T1-EBK automatic blood pressure monitor (OMRON Healthcare Europe B.V., Netherlands).

    Measured: From enrollment to the end of treatment at 12 weeks

  8. Static Balance

    Static balance will be assessed using the one-leg stance test. In this test, participants will be asked to lift the foot on the tested side approximately 5 cm above the medial malleolus of the other foot while standing and maintain this position. The test will conclude when the foot touches the ground. Successful completion of the test is demonstrated by the participant's ability to maintain the position for 30 seconds. The best score from three repetitions will be recorded.

    Measured: From enrollment to the end of treatment at 12 weeks

  9. Dynamic Balance

    Dynamic balance ability will be assessed with the Y Balance Test (YDT). The YDT is a frequently used dynamic test to objectively assess lower extremity function and balance. Performance on this test is quantified as a measure of maximum reach in a specific direction or as a calculated composite score (average reach across all reach directions). During the test, participants are asked to maintain balance while reaching in the anterior, posterolateral, and posteromedial directions using their right and left feet. To calculate the test score, the average reach distance in each direction is calculated in centimeters by averaging three trials for each direction. This value is then divided by the participant's leg length and multiplied by 100 to calculate the distance in each direction as a percentage.

    Measured: From enrollment to the end of treatment at 12 weeks

  10. Anxiety

    Beck Anxiety Inventory (BAI) It is a 21-item, four-point Likert-type scale designed to measure an individual's anxiety severity over the past week. Each item is scored from 0 to 3. A total score between 8 and 15 indicates low anxiety; 16-25 indicates moderate anxiety; and 26-63 indicates high anxiety.

    Measured: From enrollment to the end of treatment at 12 weeks

  11. Depression

    Beck Depression Inventory (BDI) The BDI is a 21-item inventory; each item represents a symptom of depression. The BDI, a self-report instrument, is the most widely used depression measurement tool worldwide. Respondents rate 21 symptoms of depression on a 4-point scale ranging from 0 to 3. Therefore, total scores range from 0 to 63, with higher scores indicating greater depression severity.

    Measured: From enrollment to the end of treatment at 12 weeks

  12. Perceived Stress

    Stress level is going to evaluate with the Perceived Stress Scale (PSS), it consists of 14 items and is designed to measure the degree to which a person perceives certain life situations as stressful. Participants rate each item on a 5-point Likert-type scale ranging from "Never (0)" to "Very often (4)." Seven of the positively worded items are reverse-scored. Scores range from 0 to 56. Higher scores indicate greater perceived stress.

    Measured: From enrollment to the end of treatment at 12 weeks

  13. Fatigue Level

    The Fatigue Severity Scale (FSS), consists of nine items. For each question, the patient is asked to select a number between 1 and 7 indicating how much they agree with each statement, with 1 indicating strongly disagree and 7 indicating strongly agree. A score of 4 or higher generally indicates severe fatigue.

    Measured: From enrollment to the end of treatment at 12 weeks

  14. Sleep Quality

    Pittsburgh Sleep Quality Index (PSQI) The PSQI is a self-assessment tool that provides detailed information about sleep quality and the type and intensity of sleep disturbances over the past month. The index consists of 24 items, five of which are answered by the individual's sleep partner or roommate. The PSQI provides scores for seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, sleeping pill use, and daytime dysfunction. Each item is scored between 0 and 3. The sum of the scores for these seven components provides the PSQI score. The total PSQI score ranges from 0 to 21. A total score of 5 or less is considered to have "good" sleep quality, while a score above 5 indicates "poor" sleep quality. A PSQI score above 5 indicates that the individual has severe sleep problems in at least two different components or mild or moderate problems in more than three components. The sc

    Measured: From enrollment to the end of treatment at 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2026
  2. Study start16 Aug 2025
  3. Primary completion21 Oct 2025
  4. Study completion5 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
74 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07320742
Sponsor's protocol ID
E-10840098-202.3.02-4030
Status last verified
Aug 2025
First submitted
8 Dec 2025
Last updated
24 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Slow Pranayama and Fast Pranayama in people with No Condition, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Forced Expiratory Flow at 25-75% of FVC (FEF25-75) (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in